Acute renal effects of intravenous bisphosphonates in the rat
- PMID: 16364053
- DOI: 10.1111/j.1742-7843.2005.pto_160.x
Acute renal effects of intravenous bisphosphonates in the rat
Abstract
Bisphosphonates are potent osteoclast inhibitors that have been associated with renal toxicity following rapid intravenous administration of high doses, which was hypothesised to be due to precipitation of bisphosphonate aggregates or complexes in the kidney. Five studies were conducted in rats investigating the characteristics of bisphosphonate-related acute renal effects. These studies included single intravenous injections of the nitrogen-containing bisphosphonates (1) ibandronate (1-20 mg/kg), or (2) zoledronate (1-10 mg/kg); (3) a single nephrotoxic dose of the non-nitrogen-containing bisphosphonate, clodronate (2 x 200 mg/kg intraperitoneal injection); (4) a single low dose of ibandronate (1 mg/kg); (5) a single high dose of zoledronate (10 mg/kg). Clinical biochemistry and kidney histopathology were performed 1 and/or 4 days after bisphosphonate dosing. The proximal convoluted tubules were the primary target for renal injury. Tubular degeneration and single cell necrosis of the these tubules were observed with all three bisphosphonates on the fourth, but not the first day after dosing. Differences between the bisphosphonates in the type and/or localisation of the lesions were apparent. Granular deposits in the lumen of distal tubules were apparent with the highest dose of zoledronate (10 mg/kg). However, intraluminal debris was proteinaceous with no evidence of any precipitation of bisphosphonate, or formation of aggregates or complexes in the kidney. Generally, biochemical parameters of renal safety and urinary enzymes did not differ significantly from controls. In summary, bisphosphonate-related renal changes did not appear to be due to the precipitation, aggregation or complexation of bisphosphonate, and biochemical parameters of renal safety did not reliably detect this renal injury.
Similar articles
-
Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.J Craniomaxillofac Surg. 2011 Dec;39(8):562-9. doi: 10.1016/j.jcms.2010.10.007. Epub 2010 Oct 28. J Craniomaxillofac Surg. 2011. PMID: 21030265
-
Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety.Toxicol In Vitro. 2008 Jun;22(4):899-909. doi: 10.1016/j.tiv.2008.01.006. Epub 2008 Jan 26. Toxicol In Vitro. 2008. PMID: 18325729
-
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.J Natl Cancer Inst. 2007 Feb 21;99(4):322-30. doi: 10.1093/jnci/djk054. J Natl Cancer Inst. 2007. PMID: 17312309
-
The kidney and bisphosphonates.Bone. 2011 Jul;49(1):77-81. doi: 10.1016/j.bone.2010.12.024. Epub 2011 Jan 11. Bone. 2011. PMID: 21232648 Review.
-
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.Oncologist. 2004;9 Suppl 4:28-37. doi: 10.1634/theoncologist.9-90004-28. Oncologist. 2004. PMID: 15459427 Review.
Cited by
-
Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.Osteoporos Int. 2018 Sep;29(9):2139-2146. doi: 10.1007/s00198-018-4589-3. Epub 2018 Jun 11. Osteoporos Int. 2018. PMID: 29947866 Free PMC article.
-
The role of vitamin E in the prevention of zoledronic acid-induced nephrotoxicity in rats: a light and electron microscopy study.Arch Med Sci. 2018 Mar;14(2):381-387. doi: 10.5114/aoms.2016.60227. Epub 2016 May 30. Arch Med Sci. 2018. PMID: 29593813 Free PMC article.
-
Managing Musculoskeletal and Kidney Aging: A Call for Holistic Insights.Clin Interv Aging. 2022 May 4;17:717-732. doi: 10.2147/CIA.S357501. eCollection 2022. Clin Interv Aging. 2022. PMID: 35548383 Free PMC article. Review.
-
Inhibitory actions by ibandronate sodium, a nitrogen-containing bisphosphonate, on calcium-activated potassium channels in Madin-Darby canine kidney cells.Toxicol Rep. 2015 Aug 28;2:1182-1193. doi: 10.1016/j.toxrep.2015.08.010. eCollection 2015. Toxicol Rep. 2015. PMID: 28962460 Free PMC article.
-
Zoledronic Acid-Associated Fanconi Syndrome in Patients With Cancer.Am J Kidney Dis. 2022 Oct;80(4):555-559. doi: 10.1053/j.ajkd.2021.12.015. Epub 2022 Feb 24. Am J Kidney Dis. 2022. PMID: 35219759 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources